SCHEMBL24668378

SCHEMBL24668378

NCCOCCOCCC(=O)NCCCC[C@@H](NC(=O)CCOCCOCCN)C(=O)NCCOCCOCCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.57
▸ FOLH1 Q04609 3/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.41
▸ SIRT1 Q96EB6 1/20 0.41
▸ NMT2 O60551 2/20 0.41
▸ NMT1 P30419 2/20 0.41
▸ EPOR P19235 2/20 0.40
▸ CHRNB2 P17787 1/20 0.39
▸ CHRNB4 P30926 1/20 0.39
▸ CHRNA3 P32297 1/20 0.39
▸ CHRNA4 P43681 1/20 0.39
▸ CHRNA1 P02708 1/20 0.39
▸ CHRNG P07510 1/20 0.39
▸ CHRNB1 P11230 1/20 0.39
▸ CHRND Q07001 1/20 0.39
▸ TLR2 O60603 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29328877 0.98 GLP1R (0.58) GLP1RFOLH1SIRT6SIRT1NMT2
SCHEMBL29329023 0.96 GLP1R (0.56) GLP1RFOLH1NMT2NMT1EPOR
SCHEMBL25269706 0.94 GLP1R (0.58) GLP1RFOLH1SIRT6SIRT1NMT2
SCHEMBL25269707 0.94 GLP1R (0.58) GLP1RFOLH1SIRT6SIRT1NMT2
SCHEMBL30094802 0.90 GLP1R (0.59) GLP1RSIRT6SIRT1NMT2NMT1
SCHEMBL16328746 0.89 GLP1R (0.51) GLP1RSIRT6SIRT1NMT2NMT1
SCHEMBL24667763 0.87 GLP1R (0.45) GLP1RFOLH1SIRT6SIRT1EPOR
SCHEMBL29336336 0.87 GLP1R (0.66) GLP1RFOLH1TLR2
SCHEMBL24038551 0.85 GLP1R (0.50) GLP1RSIRT6SIRT1NMT2NMT1
SCHEMBL24038550 0.85 GLP1R (0.50) GLP1RSIRT6SIRT1NMT2NMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022246086-A1 ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS BIOHAVEN THERAPEUTICS LTD. (US) 2022-11-24 — — WO disclosed
Send feedback